Ana G. C.
- Country
- Spain
- Department
- Department of Urology
Research Overview
- Phase 3 Randomized Trial of Nadofaragene Firadenovec with Gemcitabine, Docetaxel, or Pembrolizumab in BCG-Unresponsive High-Grade NMIBC
- (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies
- (21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Data & Insights
Has run more than one trial at 12 of 95 partner sites.
Specializations
Oncological Research
This investigator specializes in the study of advanced cancer treatments, with particular emphasis on urological oncology and bladder cancer management.
- Bladder Carcinoma Treatment
- Intravesical Therapy Development
- Novel Cancer Therapeutics
The investigator focuses on innovative approaches for treating resistant forms of bladder cancer, particularly in cases where conventional therapies have proven ineffective.
Therapeutic Innovation
Expertise centers on the development and implementation of targeted cancer therapies, including work with hormone-based treatments and specialized medications.
- Treatment Continuation Studies
- Drug Safety Assessment
- Long-term Treatment Outcomes
Research activities encompass the evaluation of novel therapeutic compounds and their long-term safety profiles in cancer treatment.
Clinical Expertise
The investigator has developed specialized knowledge in treating treatment-resistant cancers and managing complex oncological conditions.
- BCG-Unresponsive Disease Management
- Alternative Treatment Pathways
- Response Rate Assessment
Clinical focus includes the evaluation of therapeutic responses in patients who have not responded to standard treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.